Bewersdorf, Jan Philipp http://orcid.org/0000-0003-3352-0902
Zeidan, Amer M.
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30CA016359)
Article History
Received: 31 December 2018
Revised: 17 February 2019
Accepted: 1 March 2019
First Online: 8 April 2019
Compliance with ethical standards
:
: A.M.Z. received research funding (institutional) from Celgene, Acceleron, Abbvie, Otsuka, Pfizer, Medimmune/AstraZeneca, Boehringer-Ingelheim, Trovagene, Incyte, Takeda, and ADC Therapeutics. A.M.Z. had a consultancy with and received honoraria from AbbVie, Otsuka, Pfizer, Celgene, Agios, Boehringer-Ingelheim, Novartis, Acceleron, Astellas, Daiichi Sankyo, Ariad, Cardinal Health, Beyond Spring, Seattle Genetics, and Takeda. A.M.Z. received honoraria from and was a speaker for Takeda (past). A.M.Z. is one of the MEDALIST investigators. None of these relationships were related to the development of this manuscript. The other author declares that he has no conflict of interest.